Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Rating of "Hold" by Analysts

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) have been given an average rating of "Hold" by the nine analysts that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, five have given a hold rating and three have assigned a buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $7.14.

A number of brokerages have issued reports on NMRA. Bank of America restated an "underperform" rating and set a $1.00 target price (down previously from $7.00) on shares of Neumora Therapeutics in a report on Wednesday, April 2nd. Needham & Company LLC reaffirmed a "buy" rating and set a $5.00 price target on shares of Neumora Therapeutics in a research report on Tuesday, May 13th. Finally, Mizuho boosted their price target on Neumora Therapeutics from $4.00 to $5.00 and gave the company an "outperform" rating in a research note on Wednesday, July 16th.

Neumora Therapeutics Stock Up 8.2%

Shares of NMRA stock opened at $1.85 on Monday. Neumora Therapeutics has a fifty-two week low of $0.61 and a fifty-two week high of $17.19. The stock has a market capitalization of $299.24 million, a P/E ratio of -1.15 and a beta of 2.75. The stock has a 50-day simple moving average of $0.88 and a 200 day simple moving average of $1.21.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.42) EPS for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.02). On average, sell-side analysts anticipate that Neumora Therapeutics will post -1.61 earnings per share for the current year.

Hedge Funds Weigh In On Neumora Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Lunate Capital Ltd purchased a new position in Neumora Therapeutics during the 1st quarter worth $2,124,000. Swiss National Bank acquired a new position in Neumora Therapeutics in the 4th quarter worth about $1,168,000. Schonfeld Strategic Advisors LLC raised its holdings in Neumora Therapeutics by 273.9% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 521,013 shares of the company's stock worth $5,523,000 after purchasing an additional 381,676 shares during the period. Capital International Investors raised its holdings in shares of Neumora Therapeutics by 692.1% during the fourth quarter. Capital International Investors now owns 3,700,359 shares of the company's stock valued at $39,224,000 after acquiring an additional 3,233,179 shares during the last quarter. Finally, Ameriprise Financial Inc. acquired a new position in shares of Neumora Therapeutics during the fourth quarter valued at approximately $1,258,000. Hedge funds and other institutional investors own 47.65% of the company's stock.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.